The FDA’s decision reflects a thoughtful, not knee-jerk approach to its mission, which is to protect the public from fraudulent and unsafe substances. What’s at issue is how well eteplirsen works. And that it’s too expensive.
The FDA Did The Right Thing By Approving a Novel Drug For A Disabling Disease